Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapeutic approach for managing type 2 diabetes mellitus (T2DM), offering benefits that extend beyond glycaemic control. This systematic review aims to examine the effects of SGLT2 inhibitors on metabolic syndrome in individ...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Health Sciences Review |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772632025000212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761677599309824 |
|---|---|
| author | Sadia Bari Afroza Rahman Md Anwar Hossen KM Saif-Ur-Rahman |
| author_facet | Sadia Bari Afroza Rahman Md Anwar Hossen KM Saif-Ur-Rahman |
| author_sort | Sadia Bari |
| collection | DOAJ |
| description | Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapeutic approach for managing type 2 diabetes mellitus (T2DM), offering benefits that extend beyond glycaemic control. This systematic review aims to examine the effects of SGLT2 inhibitors on metabolic syndrome in individuals with prediabetes and obesity. We conducted a comprehensive search across PubMed, EMBASE, Cochrane Library, Web of Science (Core Collection), and Scopus. Title and abstract screening, data extraction, and risk of bias (ROB) assessment were performed independently by two reviewers. ROB was assessed using the Cochrane Risk of Bias tool. A meta-analysis was conducted using a random-effects model.Our meta-analysis did not show statistically significant reductions in body weight (mean difference: –3.05 kg; 95 % CI: –8.18 to 2.09), BMI (mean difference: –1.43 kg/m²; 95 % CI: –4.11 to 1.25), systolic blood pressure (mean difference: –2.12 mmHg; 95 % CI: –7.39 to 3.16), or diastolic blood pressure (mean difference: –1.04 mmHg; 95 % CI: –5.07 to 2.99) with dapagliflozin. However, a reduction was observed in fasting plasma glucose (mean difference: –0.47 mmol/L; 95 % CI: –0.90 to –0.05).Although current findings suggest that SGLT2 inhibitors (dapagliflozin) may have little to no impact on individual components of metabolic syndrome, the evidence remains limited. Further well-powered clinical trials are warranted to validate these observations. Future research should focus on comparing the efficacy of different SGLT2 inhibitors and exploring their potential synergistic effects when combined with other pharmacological agents in the treatment of metabolic syndrome. |
| format | Article |
| id | doaj-art-3d8c1be220a64ef6bb4ca3f29bb4e19c |
| institution | DOAJ |
| issn | 2772-6320 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Health Sciences Review |
| spelling | doaj-art-3d8c1be220a64ef6bb4ca3f29bb4e19c2025-08-20T03:05:56ZengElsevierHealth Sciences Review2772-63202025-06-011510022910.1016/j.hsr.2025.100229Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysisSadia Bari0Afroza Rahman1Md Anwar Hossen2KM Saif-Ur-Rahman3Internal Medicine, Flushing Hospital Medical Center, New York, USASatkhira Medical College, Satkhira, BangladeshSheikh Sayera Khatun Medical College, Gopalganj, BangladeshCollege of Medicine, Nursing and Health Sciences, University of Galway, Ireland; Evidence Synthesis Ireland and Cochrane Ireland, University of Galway, Ireland; Corresponding author at: College of Medicine, Nursing and Health Sciences, University of Galway, Ireland, and Evidence Synthesis Ireland and Cochrane Ireland, University of Galway, Ireland.Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel therapeutic approach for managing type 2 diabetes mellitus (T2DM), offering benefits that extend beyond glycaemic control. This systematic review aims to examine the effects of SGLT2 inhibitors on metabolic syndrome in individuals with prediabetes and obesity. We conducted a comprehensive search across PubMed, EMBASE, Cochrane Library, Web of Science (Core Collection), and Scopus. Title and abstract screening, data extraction, and risk of bias (ROB) assessment were performed independently by two reviewers. ROB was assessed using the Cochrane Risk of Bias tool. A meta-analysis was conducted using a random-effects model.Our meta-analysis did not show statistically significant reductions in body weight (mean difference: –3.05 kg; 95 % CI: –8.18 to 2.09), BMI (mean difference: –1.43 kg/m²; 95 % CI: –4.11 to 1.25), systolic blood pressure (mean difference: –2.12 mmHg; 95 % CI: –7.39 to 3.16), or diastolic blood pressure (mean difference: –1.04 mmHg; 95 % CI: –5.07 to 2.99) with dapagliflozin. However, a reduction was observed in fasting plasma glucose (mean difference: –0.47 mmol/L; 95 % CI: –0.90 to –0.05).Although current findings suggest that SGLT2 inhibitors (dapagliflozin) may have little to no impact on individual components of metabolic syndrome, the evidence remains limited. Further well-powered clinical trials are warranted to validate these observations. Future research should focus on comparing the efficacy of different SGLT2 inhibitors and exploring their potential synergistic effects when combined with other pharmacological agents in the treatment of metabolic syndrome.http://www.sciencedirect.com/science/article/pii/S2772632025000212Metabolic syndromePrediabetesSodium-glucose cotransporter-2 inhibitor |
| spellingShingle | Sadia Bari Afroza Rahman Md Anwar Hossen KM Saif-Ur-Rahman Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis Health Sciences Review Metabolic syndrome Prediabetes Sodium-glucose cotransporter-2 inhibitor |
| title | Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
| title_full | Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
| title_fullStr | Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
| title_full_unstemmed | Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
| title_short | Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis |
| title_sort | effect of sodium glucose cotransporter 2 inhibitor on metabolic syndrome in people with prediabetes and obesity a systematic review and meta analysis |
| topic | Metabolic syndrome Prediabetes Sodium-glucose cotransporter-2 inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2772632025000212 |
| work_keys_str_mv | AT sadiabari effectofsodiumglucosecotransporter2inhibitoronmetabolicsyndromeinpeoplewithprediabetesandobesityasystematicreviewandmetaanalysis AT afrozarahman effectofsodiumglucosecotransporter2inhibitoronmetabolicsyndromeinpeoplewithprediabetesandobesityasystematicreviewandmetaanalysis AT mdanwarhossen effectofsodiumglucosecotransporter2inhibitoronmetabolicsyndromeinpeoplewithprediabetesandobesityasystematicreviewandmetaanalysis AT kmsaifurrahman effectofsodiumglucosecotransporter2inhibitoronmetabolicsyndromeinpeoplewithprediabetesandobesityasystematicreviewandmetaanalysis |